Another study called the Concert Study is now enrolling.
The Concert Study is a global, late-stage clinical research study of 1050 patients to test the effects of Dimebon in patients with Alzheimer's disease who are currently taking Aricept® (donepezil HCl tablets). The Concert Study is taking place at 100 sites in the United States, the European Union, Australia, and New Zealand.
To learn more about the Concert Study, please visit www.CONCERTstudy.com.
Aricept® is a registered trademark of Eisai Co, Ltd.
A Connection to Tomorrow's Hope
What is the Connection Study?
The Connection Study is a Phase 3 clinical research study of 525 patients to test the effects of Dimebon in patients with Alzheimer's disease. The goal of the Connection Study is to determine if Dimebon safely improves cognition (thinking and awareness), memory, daily functioning, behavior, and the ability to care for oneself. The Connection Study will also look at how Dimebon affects the lives of people caring for patients who are taking the medicine.
What is Dimebon?
Dimebon is an oral medication that is being tested for Alzheimer's disease. Currently, 5 prescription drugs are approved in the United States to treat Alzheimer's disease. Dimebon works differently than any of these Alzheimer's disease treatments.
Another study called the Concert Study is now enrolling.
The Concert Study is a global, late-stage clinical research study of 1050 patients to test the effects of Dimebon in patients with Alzheimer's disease who are currently taking Aricept® (donepezil HCl tablets). The Concert Study is taking place at 100 sites in the United States, the European Union, Australia, and New Zealand.
To learn more about the Concert Study, please visit www.CONCERTstudy.com.